Blood Eosinophils and Clinical Outcomes in Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study

References

• Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35(1):157–163.
   PubMed Web of Science ®Google Scholar
• Agusti A, Beasley R, Celli BR, et al. Global invitation of chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (2021 report); 2021.
   Google Scholar
• Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60:193–198. doi:10.1136/thx.2004.032516
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485. doi:10.1016/S0140-6736(00)02872-5
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Wu HX, Zhuo KQ, Cheng DY. Peripheral blood Eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. Int J Chronic Obstr. 2019;14:3003.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Resp Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;71:118–125. doi:10.1136/thoraxjnl-2015-207021
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzla K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Resp Med. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-4
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Resp Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-0
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang LR, Zhang S, et al. Blood Eosinophilia and its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. Int J Chronic Obstr. 2020;15:1123–1134.
   PubMed Web of Science ®Google Scholar
• Yang J, Yang J. Association between blood Eosinophils and mortality in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study. Int J Chronic Obstr. 2021;16:281–288.
   PubMed Web of Science ®Google Scholar
• Martínez-Gestoso S, García-Sanz MT, Calvo-álvarez U, et al. Variability of blood eosinophil count and prognosis of COPD exacerbations. Ann Med. 2021;53(1):1152–1158. doi:10.1080/07853890.2021.1949489
   PubMed Web of Science ®Google Scholar
• Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chronic Obstr. 2017;12:1819–1824.
   Web of Science ®Google Scholar
• Yu S, Zhang J, Fang Q, et al. Blood Eosinophil levels and prognosis of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. Am J Med Sci. 2021;362(1):56–62. doi:10.1016/j.amjms.2021.02.013
   PubMed Web of Science ®Google Scholar
• Mao Y, Qian Y, Sun X, et al. Eosinopenia predicting long-term mortality in hospitalized acute exacerbation of COPD patients with community-acquired pneumonia-a retrospective analysis. Int J Chronic Obstr. 2021;16:3551–3559.
   PubMed Web of Science ®Google Scholar
• Peng J, Yu Q, Fan S, et al. High blood Eosinophil and YKL-40 levels, as well as low CXCL9 levels, are associated with increased readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chronic Obstr. 2021;16:795–806.
   PubMed Web of Science ®Google Scholar
• Zhou C, Yi Q, Ge H, et al. Validation of risk assessment models predicting venous thromboembolism in inpatients with acute exacerbation of chronic obstructive pulmonary disease: a multicenter cohort study in China. Thromb Haemost. 2022;122(07):1177–1185. doi:10.1055/a-1693-0063
   Web of Science ®Google Scholar
• Salturk C, Karakurt Z, Adiguzel N, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? Int J Chronic Obstr. 2015;10:1837–1846.
   PubMed Web of Science ®Google Scholar
• Hakansson KEJ, Ulrik CS, Godtfredsen NS, et al. High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD. Int J Chronic Obstr. 2020;15:733–743.
   PubMed Web of Science ®Google Scholar
• Steer J, Gibson J, Bourke SC. The DECAF score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970–976. doi:10.1136/thoraxjnl-2012-202103
   PubMed Web of Science ®Google Scholar
• Chen PK, Hsiao YH, Pan SW, et al. Independent factors associate with hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease requiring intensive care unit admission: focusing on the eosinophil-to-neutrophil ratio. PLoS One. 2019;14(7):e0218932. doi:10.1371/journal.pone.0218932
   PubMed Web of Science ®Google Scholar
• Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12(2):1–10. doi:10.1186/cc6883
   Web of Science ®Google Scholar
• Al Duhailib Z, Farooqi M, Piticaru J, et al. The role of eosinophils in sepsis and acute respiratory distress syndrome: a scoping review. Can J Anesth. 2021;68(5):715–726. doi:10.1007/s12630-021-01920-8
   Web of Science ®Google Scholar
• Shaaban H, Daniel S, Sison R, et al. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. 2010;25(4):570–575. doi:10.1016/j.jcrc.2010.03.002
   Web of Science ®Google Scholar
• Wei T, Wang X, Lang K, et al. Low Eosinophil phenotype predicts noninvasive mechanical ventilation use in patients with hospitalized exacerbations of COPD. J Inflamm Res. 2022;15:1259–1271. doi:10.2147/JIR.S343918
   PubMed Web of Science ®Google Scholar
• ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020;25(3):259–266. doi:10.1111/resp.13660
   PubMed Web of Science ®Google Scholar
• Lv MY, Qiang LX, Li ZH, et al. The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). J Thorac Dis. 2021;13(1):232–243. doi:10.21037/jtd-20-2178
   PubMed Web of Science ®Google Scholar
• Toraldo DM, Conte L. Influence of the lung microbiota dysbiosis in chronic obstructive pulmonary disease exacerbations: the controversial use of corticosteroid and antibiotic treatments and the role of Eosinophils as a disease marker. J Clin Med Res. 2019;11(10):667–675. doi:10.14740/jocmr3875
   PubMedGoogle Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care. 2012;186(1):48–55. doi:10.1164/rccm.201108-1553OC
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Resp Med. 2017;5(9):747–759. doi:10.1016/S2213-2600(17)30217-5
   PubMed Web of Science ®Google Scholar
• Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Resp Med. 2019;7(8):699–709. doi:10.1016/S2213-2600(19)30176-6
   PubMed Web of Science ®Google Scholar